{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:41:03Z","timestamp":1762508463424,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jdcr.2021.04.006","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T19:39:27Z","timestamp":1619293167000},"page":"81-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical features of tumor necrosis factor-\u03b1-inhibitor induced chilblain lupus: A case series"],"prefix":"10.1016","volume":"12","author":[{"given":"Nadine","family":"Shabeeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Hinshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jdcr.2021.04.006_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10067-008-0942-9","article-title":"Chilblain lupus erythematosus\u2013a review of literature","volume":"27","author":"Hedrich","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.jdcr.2021.04.006_bib2","first-page":"889","article-title":"Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF\u03b1 agents","volume":"10","author":"Dalle Vedove","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jdcr.2021.04.006_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-011-1924-x","article-title":"Chilblain lupus induced by TNF-\u03b1 antagonists: a case report and literature review","volume":"31","author":"Sifuentes Giraldo","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jdcr.2021.04.006_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/DAD.0b013e3181af1d24","article-title":"Perniosis: clinical and histopathological analysis","volume":"32","author":"Boada","year":"2010","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"10.1016\/j.jdcr.2021.04.006_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1067\/mjd.2001.117861","article-title":"A histologic and immunohistochemical study of chilblains","volume":"45","author":"Cribier","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2021.04.006_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamadermatol.2018.5077","article-title":"Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation","volume":"155","author":"Zimmerman","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2021.04.006_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14740338.2015.995089","article-title":"Drug-induced lupus","volume":"14","author":"Rubin","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdcr.2021.04.006_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1874312901206010315","article-title":"Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus","volume":"6","author":"Almoallim","year":"2012","journal-title":"Open Rheumatol J"},{"issue":"12","key":"10.1016\/j.jdcr.2021.04.006_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11926-018-0799-0","article-title":"Review of biosimilar trials and data on etanercept in rheumatoid arthritis","volume":"20","author":"Chadwick","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jdcr.2021.04.006_bib10","first-page":"139","article-title":"Remicade (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"issue":"7","key":"10.1016\/j.jdcr.2021.04.006_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.jdcr.2021.04.006_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Med (Baltim)"},{"issue":"3 Suppl 1","key":"10.1016\/j.jdcr.2021.04.006_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1590\/abd1806-4841.20153893","article-title":"Anti-TNF-\u03b1 and hydralazine drug-induced lupus","volume":"90","author":"Quaresma","year":"2015","journal-title":"An Bras Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621002678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621002678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:22:56Z","timestamp":1762474976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512621002678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":13,"alternative-id":["S2352512621002678"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.04.006","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features of tumor necrosis factor-\u03b1-inhibitor induced chilblain lupus: A case series","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}